Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Caterpillar To Butterfly? Ablynx Says Caplacizumab Data Transformational

Executive Summary

Belgian Nanobody drug developer Ablynx says it will be transformed by positive Phase III topline HERCULES data on caplacizumab for treating the rare blood-clotting disorder, acquired TTP.

You may also be interested in...



Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom

A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.

A Star Is Born? HERCULES Data Shine At ASH For Ablynx's Caplacizumab

Strong Phase III HERCULES data mean Ablynx's caplacizumab is likely to sail through regulatory proceedings next year, becoming the first approved therapy for the rare blood disease, acquired thrombotic thrombocytopenic purpura.

Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights

Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel